Abbott has completed the $400 million acquisition of privately held eye care company Visiogen, expanding the company’s vision care business with latest intraocular lens (IOL) technology to address presbyopia for cataract patients. Abbott had entered into the vision care segment in February 2009 with its acquisition of Advanced Medical Optics.
Reportedly, Synchrony has received CE mark designation and has been available commercially in Europe since January 2009. It also is currently under review by the US FDA. It is designed to mimic the eye’s natural ability to change focus (accommodation), delivering improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity.
Jim Mazzo, senior vice president ofAbbott Medical Optics, said: “Visiogen immediately provides Abbott Medical Optics with a talented team of dedicated professionals and an entry point into the accommodating IOL market. The innovative Synchrony accommodating IOL expands our diverse portfolio of cataract treatments and allows Abbott the opportunity to help the more than 1billion people worldwide suffering from presbyopia.”